The Impact of GLP-1 on Diabetes Management

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Function of Glucagon-Like Peptide-1 in Glucose Regulation

Glucagon-like peptide-1 (GLP-1) is a 30–amino acid hormone generated in the intestinal endocrine L-cells through selective processing of proglucagon. Current evidence explores how proglucagon gene expression is regulated in both the gut and the brain, as well as the mechanisms involved in post-translational modification.

GLP-1 is secreted following food intake, triggered by specific stimuli and molecular pathways. The hormone is rapidly degraded by the enzyme dipeptidyl peptidase IV, often before leaving the gut. This suggests that some of its effects may be mediated by sensory neurons in the intestine and liver that express the GLP-1 receptor.

It is important to differentiate between measurements of the active hormone, which drives endocrine functions, and the combined levels of active hormone plus metabolites, which reflect total L-cell activity and potential neural signaling.

Primary Actions of GLP-1

The main functions of GLP-1 include:

• Enhancing insulin secretion in a glucose-dependent manner (incretin effect).
  
• Suppressing glucagon release, which helps control post-meal blood glucose elevations.
  
• Slowing gastric emptying and reducing gastrointestinal secretions, contributing to the “ileal brake” mechanism.
  
• Regulating appetite and reducing food intake.
  

Because of these diverse roles, GLP-1 and GLP-1 receptor agonists are under investigation as therapeutic strategies for type 2 diabetes. Reduced secretion of GLP-1 may contribute to obesity, while excessive secretion has been linked to postprandial reactive hypoglycemia.

GLP-1 Receptor Agonists in Type 2 Diabetes Therapy

A newer category of antidiabetic agents, known as incretin-based therapies, acts on GLP-1 receptors to promote insulin secretion from pancreatic β-cells in a glucose-dependent fashion, particularly under hyperglycemic conditions. These drugs also suppress glucagon secretion.

Initially, it was believed that GLP-1 receptor agonists carried a lower risk of hypoglycemia compared with traditional insulin secretagogues such as sulfonylureas. However, some studies suggested that these agents may trigger hypoglycemia in healthy, normoglycemic individuals, raising questions about whether their effects are fully glucose-dependent. Other research, however, concluded that the risk is minimal and influenced by patient-specific factors.

Regulatory bodies, including the FDA, have noted potential safety concerns with the 12 GLP-1 receptor agonists currently approved and continue to evaluate their risk–benefit profile.

Evidence on Hypoglycemia Risk

A review of available studies shows no consistent evidence that GLP-1 receptor agonists alone cause hypoglycemia. These agents have demonstrated strong efficacy in glycemic management among individuals with type 2 diabetes, particularly older patients who are often on multiple medications.

Unlike insulin or sulfonylureas, GLP-1 receptor agonists are not associated with weight gain, and the risk of hypoglycemia has not been clearly established. Most evidence suggests that due to underlying insulin resistance and impaired β-cell function, hypoglycemia is unlikely in patients with type 2 diabetes receiving these therapies.

One small clinical trial, however, reported three cases of hypoglycemia out of ten healthy subjects administered a GLP-1 receptor agonist.

Conclusion

GLP-1 plays a crucial role in maintaining glucose homeostasis through insulin enhancement, glucagon suppression, appetite regulation, and gastrointestinal modulation. GLP-1 receptor agonists have become an effective treatment option for type 2 diabetes, with benefits including improved glycemic control and reduced risk of weight gain.

While concerns remain regarding potential hypoglycemia, the majority of evidence indicates that this risk is minimal in patients with diabetes. Continued research is warranted to further clarify long-term safety and patient-specific responses to GLP-1–based therapies.

Read More: aicar  

REFERENCES

1. Ja’arah D, Al Zoubi MS, Abdelhady G, Rabi F, Tambuwala MM. Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. Clinical Medicine Insights: Endocrinology and Diabetes. 2021;14. doi:10.1177/11795514211051697